Cystoscopy — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Cystoscopy is an endoscopic procedure in which a thin telescope (cystoscope) with a lens and light source is introduced through the urethra into the bladder to allow direct visualisation of the urethra, bladder neck, and bladder interior. Two types of cystoscope are used: flexible cystoscopes (fibre-optic or digital, steerable at the tip) suitable for outpatient use under local anaesthetic gel; and rigid cystoscopes (metal, straight or angled lenses) requiring general or spinal anaesthesia and used primarily for operative procedures. Continuous saline or glycine irrigation maintains clear vision throughout. The procedure enables diagnosis and, in many cases, simultaneous treatment of conditions affecting the lower urinary tract. Cystoscopy is one of the most commonly performed urological procedures worldwide, used extensively for the investigation of haematuria (blood in urine), bladder cancer surveillance, and urological interventions. Advances in digital narrow-band imaging (NBI) and blue-light photodynamic cystoscopy have improved detection of flat carcinoma in situ (CIS) lesions that are easily missed on white-light cystoscopy. Cystoscopy is performed by urologists in an outpatient endoscopy setting or in theatre. Over 250,000 flexible cystoscopies are performed annually in England for bladder cancer surveillance and investigation of urological symptoms.

Cystoscopy is indicated whenever direct visualisation of the bladder and urethra is required for diagnosis or treatment. Major diagnostic indications include: visible haematuria (blood in urine visible to the naked eye) — requires urgent flexible cystoscopy within 2 weeks in most guidelines; microscopic haematuria in patients over 40 years or with risk factors for bladder cancer (smoking, occupational chemical exposure, previous pelvic radiotherapy, cyclophosphamide use); recurrent urinary tract infections (UTIs) not explained by culture and urine dip; urinary symptoms including frequency, urgency, or reduced stream not adequately explained by imaging; investigation for bladder stones, diverticula, fistulae, or urethral stricture; and biopsy of suspicious bladder lesions. Therapeutic indications include: surveillance cystoscopy for known non-muscle-invasive bladder cancer (NMIBC); intravesical therapy instillation for NMIBC (BCG, mitomycin C); stent insertion for ureteric obstruction; urethral dilation; and cystoscopy prior to major gynaecological or colorectal surgery. Cystoscopy is contraindicated in the presence of active urinary tract infection or urethral stricture precluding scope passage.

Flexible cystoscopy (outpatient): The patient lies supine (men) or in lithotomy position (women). Lidocaine 2% gel is instilled into the urethra (men) or applied topically (women) and left for 3–5 minutes for anaesthesia and lubrication. The flexible cystoscope (typically 16–17 French diameter) is gently advanced along the urethra, through the external and internal urethral sphincters, and into the bladder. Saline is irrigated to distend the bladder (typically 150–200 ml) for optimal visualisation. A systematic inspection of all bladder walls (posterior wall, dome, lateral walls, trigone, ureteral orifices, bladder neck) and the urethra on withdrawal is performed. The cystoscope is removed and the patient voids before leaving. The entire procedure takes 5–15 minutes. Rigid cystoscopy (operating theatre): performed under general or spinal anaesthesia, allowing insertion of larger instruments for biopsy (cup forceps, cold cup), laser treatment, diathermy, stone fragmentation, and stent insertion. Transurethral resection of bladder tumour (TURBT) is performed through a resectoscope (a specialised rigid instrument) under general anaesthesia, resecting visible bladder tumours with a diathermy loop to provide tissue for histological staging. Rigid cystoscopy is performed under general or spinal anaesthesia in theatre and allows passage of larger instruments for resection, biopsy, and laser treatment. The total outpatient flexible cystoscopy appointment time from arrival to discharge is typically 30–45 minutes.

Flexible cystoscopy provides direct, real-time visualisation of the bladder mucosa and detects bladder tumours with a sensitivity of 90–95% and a specificity of 85–95% for macroscopic papillary lesions. It is the gold standard investigation for haematuria and bladder cancer surveillance, superior to CT urography for the detection of flat mucosal lesions and cannot be replaced by imaging alone. Enhanced cystoscopy techniques — narrow-band imaging (NBI) and blue-light hexaminolevulinate (HAL) photodynamic cystoscopy — increase detection of flat CIS lesions by 15–25% compared to white-light cystoscopy alone and reduce recurrence rates after TURBT when used for resection guidance. Cystoscopy is performed as a comfortable outpatient procedure in most diagnostic cases, avoids radiation, and allows immediate biopsy or treatment if a lesion is found. Surveillance cystoscopy at defined intervals (3 months, 6 months, then annually for low-grade NMIBC) is the most effective strategy for early detection of bladder cancer recurrence, which occurs in 50–70% of patients after TURBT.

Flexible cystoscopy is very well tolerated with a low complication rate. Post-procedure lower urinary tract symptoms (dysuria, urinary frequency, urgency) and haematuria (visible blood in urine) lasting 24–48 hours are common and expected after any cystoscopy and not a cause for alarm if mild. Urinary tract infection (UTI) complicates 2–5% of cystoscopies; prophylactic antibiotics are routinely given before cystoscopy in patients with positive urine cultures, urinary catheters, or immunosuppression. Urethral injury is rare and manifests as haematuria or urinary retention; it is minimised by using adequate lubrication and never forcing the scope against resistance. Bladder perforation with a flexible scope is extremely rare; rigid cystoscopy and TURBT carry a perforation risk of 1–5%, managed with catheter drainage (extraperitoneal) or surgical repair (intraperitoneal). Urinary retention may occur after any cystoscopy, particularly in men with pre-existing bladder outflow obstruction, requiring temporary catheterisation. Patients should return to the emergency department for fever above 38°C, inability to pass urine, or heavy bleeding after cystoscopy.

After flexible cystoscopy, patients return home immediately. A period of 30 minutes post-procedure observation is routine to ensure the patient voids comfortably. Mild burning or discomfort on urination and pink-tinged urine (haematuria) are expected for the first 24–48 hours and resolve spontaneously with increased fluid intake (aim for 2 litres of water daily). Paracetamol manages any discomfort. Driving is permitted after flexible cystoscopy (no sedation given). Strenuous activity and sexual intercourse should be avoided for 24 hours. Most patients return to work and normal activities the same day or the day after flexible cystoscopy. After rigid cystoscopy or TURBT under general anaesthesia, discharge usually occurs the same day or after one night with a urethral catheter in place for 24–72 hours depending on the procedure performed. The catheter is removed after confirming clear urine. Outpatient cystoscopy surveillance schedules (for bladder cancer follow-up) are agreed with the urologist based on tumour grade, stage, and risk stratification using the EORTC scoring system.